Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Vasoactive mediator release by fetal endothelial cells in intrauterine growth restriction and preeclampsia

Article Abstract:

During preeclampsia the fetus produces more cyclic guanosine monophosphate (GMP) to dilate blood vessels and allow blood to flow freely. Preeclampsia is a serious complication of pregnancy. During growth restriction the fetus does not produce cyclic GMP, which could cause blood vessels to constrict.

Author: Pearson, Jeremy D., Nicolaides, Kypros H., Parra, Mauro C., Lees, Christoph, Mann, Giovanni E.
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2001
Physiological aspects, Preeclampsia

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Increased nuchal translucency with normal karyotype

Article Abstract:

The association between increased fetal nuchal translucency (NT) thickness in chromosomally normal fetuses and a wide range of fetal malformations, deformations, dysgeneses, and genetic syndromes is reviewed. The vast majority of fetal abnormalities associated with increased nuchal translucency can be diagnosed by a series of investigations that can be completed by 14 weeks of gestation.

Author: Nicolaides, Kypros H., Souka, Athena P., Kaisenberg, Constantin S. von, Hyett, Jonathan A., Sonek, Jiri D.
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2005
United States, Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Gynecological R&D, Diagnosis, Medical examination, Fetal development, Gynecological research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction

Article Abstract:

A study is conducted to determine whether maternal serum concentration of the angiogenic factor vascular endothelial growth factor (VEGF) and its circulating antagonist, soluble fms-like tyrosine kinase 1 (sFlt-1) are altered in pregnancies that subsequently develop preeclampsia (PE) and in those with established fetal growth restriction (FGR). It is found that maternal serum concentration of sFlt-1 in pregnancies with FGR is increased but is not evident in pregnancies with impaired placentation that subsequently developed either FGR or PE.

Author: Nicolaides, Kypros H., Savvidou, Makrina D.
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2006
Health aspects, Analysis, Risk factors, Pregnancy, Complications of, Pregnancy complications, Tyrosine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Fetus, Fetal growth retardation
Similar abstracts:
  • Abstracts: Fetal esophageal ligation induces expression of vascular endothelial growth factor messenger ribonucleic acid in fetal membranes
  • Abstracts: Relation between damage to the placenta and the fetal brain after late-gestation placental embolization and fetal growth restriction in sheep
  • Abstracts: Predicting outcomes of trials of labor in women attempting vaginal birth after cesarean delivery: a comparison of multivariate methods with neural networks
  • Abstracts: Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia
  • Abstracts: Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2026 Advameg, Inc.